[go: up one dir, main page]

WO1999012532A3 - Piperidine derivatives against malaria - Google Patents

Piperidine derivatives against malaria Download PDF

Info

Publication number
WO1999012532A3
WO1999012532A3 PCT/EP1998/005570 EP9805570W WO9912532A3 WO 1999012532 A3 WO1999012532 A3 WO 1999012532A3 EP 9805570 W EP9805570 W EP 9805570W WO 9912532 A3 WO9912532 A3 WO 9912532A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperidine derivatives
against malaria
derivatives against
patient
chloroquine
Prior art date
Application number
PCT/EP1998/005570
Other languages
French (fr)
Other versions
WO1999012532A2 (en
Inventor
Daniel Bur
Walter Fischli
Hugues Matile
Robert George Ridley
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Daniel Bur
Walter Fischli
Hugues Matile
Robert George Ridley
Wolfgang Wostl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Daniel Bur, Walter Fischli, Hugues Matile, Robert George Ridley, Wolfgang Wostl filed Critical Hoffmann La Roche
Priority to AU97409/98A priority Critical patent/AU9740998A/en
Publication of WO1999012532A2 publication Critical patent/WO1999012532A2/en
Publication of WO1999012532A3 publication Critical patent/WO1999012532A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention concerns the use of compounds of formula (I) and of pharmaceutically acceptable salts thereof, wherein R?1, R2, R3, R4¿ and Q are as hereinbefore defined, against chloroquine-sensitive and chloroquine-resistant pathogens and in the production of corresponding medicaments, furthermore corresponding medicaments and a method of treating malaria in a patient in need of such treatment which comprises administering to said patient an effective amount of a corresponding compound or medicament.
PCT/EP1998/005570 1997-09-08 1998-09-02 Piperidine derivatives against malaria WO1999012532A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU97409/98A AU9740998A (en) 1997-09-08 1998-09-02 Piperidine derivatives against malaria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97115510 1997-09-08
EP97115510.6 1997-09-08

Publications (2)

Publication Number Publication Date
WO1999012532A2 WO1999012532A2 (en) 1999-03-18
WO1999012532A3 true WO1999012532A3 (en) 1999-07-29

Family

ID=8227323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005570 WO1999012532A2 (en) 1997-09-08 1998-09-02 Piperidine derivatives against malaria

Country Status (2)

Country Link
AU (1) AU9740998A (en)
WO (1) WO1999012532A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
BR0113989A (en) * 2000-09-25 2004-01-27 Actelion Pharmaceuticals Ltd Compounds, pharmaceutical compositions, process for preparing a pharmaceutical composition, and use of at least one of the compounds
BR0214295A (en) 2001-11-19 2004-11-09 Elan Pharm Inc Compound, method for treating a patient who has or prevent a patient from acquiring a disease or condition, and method for producing a compound
WO2004105762A1 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases
EP1707206A1 (en) * 2005-03-31 2006-10-04 Speedel Experimenta AG Piperazine derivates for the inhibition of beta-secretase, cathepsin D, plasmepsin ll and HIV protease and for the treatment of malaria, Alzeheimer and AIDS
EP1707202A1 (en) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organic compounds
EP1987834A3 (en) * 2007-02-13 2008-11-19 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2301627A1 (en) * 2009-09-22 2011-03-30 University of Graz Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE045610T2 (en) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR102502485B1 (en) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2458146A1 (en) * 1973-12-07 1975-06-12 Hoffmann La Roche CHINOLINE DERIVATIVES
US3914235A (en) * 1968-07-02 1975-10-21 Hoffmann La Roche Processes and intermediates for quinine, quinidine, isomers and derivatives thereof
WO1997009311A1 (en) * 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914235A (en) * 1968-07-02 1975-10-21 Hoffmann La Roche Processes and intermediates for quinine, quinidine, isomers and derivatives thereof
DE2458146A1 (en) * 1973-12-07 1975-06-12 Hoffmann La Roche CHINOLINE DERIVATIVES
WO1997009311A1 (en) * 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARLIN, GORDON B. ET AL: "Potential antimalarials. XVI. 4'-Chloro-3-[7''-chloro(and trifluoromethyl)quinolin-4''-yl]amino-5-[(substituted amino)methyl]biphenyl-4-ols and 4'-bromo(and 3'-trifluoromethyl)-3- [(substituted amino)methyl]-5-(7''-trifluoromethylquinolin-4''- yl)aminobiphenyl-2-ols", AUST. J. CHEM. (1992), 45(11), 1845-55 CODEN: AJCHAS;ISSN: 0004-9425, XP002101247 *
MAAG, HANS ET AL: "5-(N-Arylnortropan-3-yl)- and 5-(N-arylpiperidin-4-yl)-2,4- diaminopyrimidines. Novel inhibitors of dihydrofolate reductase", HELV. CHIM. ACTA (1986), 69(4), 887-97 CODEN: HCACAV;ISSN: 0018-019X, 1986, XP002101246 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
WO1999012532A2 (en) 1999-03-18
AU9740998A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
WO1999012532A3 (en) Piperidine derivatives against malaria
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
NO2005024I1 (en) Hexylaminolevulinate, optionally in the form of a salt, preferably hexylaminolevulinate hydrochloride
CA2216796A1 (en) Quinazoline derivatives
BG103430A (en) FACTOR Xa INHIBITING HETEROCYCLIC DERIVATIVES
HU9601685D0 (en) 4,5-diaryloxazole derivatives
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
NO180407C (en) Use of 1,3-oxathiolannucleoside analogues in the manufacture of a medicament for the treatment of hepatitis B
WO2005056524A3 (en) Therapeutic agents useful for treating pain
CA2427227A1 (en) Lactam compound
MY112102A (en) Therapeutic heterocycles.
IL111284A (en) 2-phenyl-3-aroylbenzothiophenes for use as medicaments for inhibiting endometriosis
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
MX9804226A (en) Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, preparation thereof and therapeutical use thereof.
HK1042303A1 (en) New compounds
IL111289A (en) 2-Phenyl-3- aroylbenzothiophenes for use as medicaments for inhibiting angiogenesis
NO944915L (en) Increase in thrombomodulin expression
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CA2235747A1 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
DE69935526D1 (en) SUPRAMOLECULAR COMPLEX-CONTAINING MEDICAMENTS
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
ZA941464B (en) Use of pregnane derivative
WO2001016096A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA